300 related articles for article (PubMed ID: 34069999)
1. Targeting the VEGF Pathway in Osteosarcoma.
Assi T; Watson S; Samra B; Rassy E; Le Cesne A; Italiano A; Mir O
Cells; 2021 May; 10(5):. PubMed ID: 34069999
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
3. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
Sharma PS; Sharma R; Tyagi T
Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
6. VEGF kinase inhibitors: how do they cause hypertension?
Bhargava P
Am J Physiol Regul Integr Comp Physiol; 2009 Jul; 297(1):R1-5. PubMed ID: 19439616
[TBL] [Abstract][Full Text] [Related]
7. Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.
Zhu XZ; Mei J
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4362-70. PubMed ID: 26636524
[TBL] [Abstract][Full Text] [Related]
8. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
10. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
12. The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.
Moser C; Lang SA; Stoeltzing O
Clin Colorectal Cancer; 2007 Jul; 6(8):564-71. PubMed ID: 17681102
[TBL] [Abstract][Full Text] [Related]
13. Role of TKI for Metastatic Osteogenic Sarcoma.
Duffaud F
Curr Treat Options Oncol; 2020 Jun; 21(8):65. PubMed ID: 32601895
[TBL] [Abstract][Full Text] [Related]
14. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Kaya M; Wada T; Akatsuka T; Kawaguchi S; Nagoya S; Shindoh M; Higashino F; Mezawa F; Okada F; Ishii S
Clin Cancer Res; 2000 Feb; 6(2):572-7. PubMed ID: 10690541
[TBL] [Abstract][Full Text] [Related]
16. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.
Liu Y; Huang N; Liao S; Rothzerg E; Yao F; Li Y; Wood D; Xu J
Cell Prolif; 2021 Sep; 54(9):e13102. PubMed ID: 34309110
[TBL] [Abstract][Full Text] [Related]
17. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
Eskens FA; Verweij J
Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
[TBL] [Abstract][Full Text] [Related]
18. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
Adjei AA
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028
[TBL] [Abstract][Full Text] [Related]
19. VEGF signal system: the application of antiangiogenesis.
Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
[TBL] [Abstract][Full Text] [Related]
20. [Advances of VEGF related molecular promoting tumor angiogenesis and targeting therapy].
Guo ZY; Cao BL
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):282-4. PubMed ID: 20654135
[No Abstract] [Full Text] [Related]
[Next] [New Search]